{"nctId":"NCT04193189","briefTitle":"B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B","startDateStruct":{"date":"2020-12-14","type":"ACTUAL"},"conditions":["HIV Infection","Hepatitis B"],"count":638,"armGroups":[{"label":"Group A, 2-CpG: HEPLISAV-B (two injections)","type":"EXPERIMENTAL","interventionNames":["Biological: HEPLISAV-B"]},{"label":"Group A, 3-CpG: HEPLISAV-B (three injections)","type":"EXPERIMENTAL","interventionNames":["Biological: HEPLISAV-B"]},{"label":"Group A, 3-alum: ENGERIX-B (three injections)","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: ENGERIX-B"]},{"label":"Group B: HEPLISAV-B (three injections)","type":"EXPERIMENTAL","interventionNames":["Biological: HEPLISAV-B"]}],"interventions":[{"name":"HEPLISAV-B","otherNames":[]},{"name":"ENGERIX-B","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria, Groups A and B\n\n* HIV-1 infection\n* On current HIV-1 antiretroviral therapy (ART)\n* CD4+ T-cell count ≥100 cells/mm\\^3\n* HIV-1 RNA \\<1000 copies/mL\n\nInclusion Criteria, Group A only\n\n* Serum Hepatitis B antibody \\<10 mlU/mL, non-reactive (negative), or indeterminate\n* Documentation of HBV vaccination \\>168 days prior to study entry\n\nInclusion Criterion, Group B only\n\n* Serum Hepatitis B antibody non-reactive (negative) within 45 days prior to study entry\n\nExclusion Criteria, Groups A and B\n\n* Infection or prior exposure to HBV\n* Serum HBsAb level ≥10 mlU/mL or positive at screening or any other time prior to screening\n* Presence of any active or acute AIDS-defining opportunistic infections\n* Solid organ transplantation\n* History of ascites, encephalopathy, or variceal hemorrhage\n* Diagnosis of chronic kidney disease (CKD) stage G4\n* Cancer diagnosis within 5 years\n* Currently receiving chemotherapy\n* Chronic use and/or receipt of systemically administered immunosuppressive\n* Known allergy/sensitivity or any hypersensitivity to any HBV vaccine or yeast\n* Active, serious infection other than HIV-1\n* Receipt of any inactivated virus vaccine within 14 days\n* Receipt of any of the following within 45 days prior to study entry:\n\n  * Live virus vaccine\n  * Granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF)\n  * Any other investigational medicinal agent\n* Receipt of immunoglobulin or blood products within 90 days prior to study entry\n* Receipt of an injection of DNA plasmids or oligonucleotides within 60 days prior to study entry\n\nExclusion Criteria, Group A only\n\n* Hepatitis B virus vaccination ≤168 days prior to study entry\n* Receipt of HEPLISAV-B vaccine at any time prior to study entry\n\nExclusion Criterion, Group B only\n\n* Known HBV vaccination prior to study entry","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Primary Seroprotection Response","description":"Primary seroprotection response was defined as antibody titer against hepatitis B surface antigen (anti-HBs) ≥10 mIU/mL at 8 weeks after 2-dose vaccination series and at 4 weeks after 3-dose vaccination series. If the completion of the vaccine series was delayed (a delay of ≤4 weeks was allowed), the trial protocol specified obtaining an antibody result at 8 weeks for the 2-dose series or at 4 weeks for the 3-dose series after vaccine completion for use in the primary outcome analysis. The study was designed separately for the two study populations (Groups A and B), and the analysis was conducted separately, as prespecified in the study protocol and Statistical Analysis Plan (SAP). In Group A, two-sided 97.5% confidence intervals (CI) were specified for the SPR differences between study arms (presented in the Statistical Analyses sections below). In Group B, two-sided 95% Wilson CI around the single-arm estimate was specified (presented in the Data Table below).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.1","spread":null},{"groupId":"OG001","value":"99.4","spread":null},{"groupId":"OG002","value":"80.6","spread":null},{"groupId":"OG003","value":"100","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Adverse Events (AEs)","description":"The protocol required reporting of (1) Grade ≥2 AEs, (2) AEs that led to a change in study treatment regardless of grade, (3) AEs meeting serious AE (SAE) definition or expedited AE (EAE) reporting requirement, (4) Grade ≥1 local and systemic injection reactions within 7 days of any study vaccine injection, (5) medically attended adverse events (MAAE) regardless of grade, and (6) potential immune-mediated AEs regardless of grade. Grading was per DAIDS AE Grading Table (Version 2.1): Grade 1 (mild), 2 (moderate), 3 (severe), 4 (life-threatening) and 5 (death). DAIDS EAE Manual (V1.0) was used. Wilson method was used for confidence intervals.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.3","spread":null},{"groupId":"OG001","value":"77.7","spread":null},{"groupId":"OG002","value":"73.7","spread":null},{"groupId":"OG003","value":"87.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Seroprotection Response","description":"Seroprotection response (SPR) was defined as antibody titer against hepatitis B surface antigen (anti-HBs) ≥10 mIU/mL. Study visit weeks are according to protocol-specified visit windows; anti-HBs results outside visit windows were not included. These are snapshots at scheduled visits irrespective of delayed vaccinations, unlike the visits defined in Primary Outcome 1. The study was designed separately for the two study populations (Groups A and B), and the analysis was conducted separately, as prespecified in the study protocol and Statistical Analysis Plan (SAP). In Group A, two-sided 97.5% confidence intervals (CI) were specified for the SPR differences between study arms (presented in the Statistical Analyses sections below). In Group B, two-sided 95% Wilson CIs around the single-arm estimates were specified (presented in the Data Table below).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.1","spread":null},{"groupId":"OG001","value":"66.7","spread":null},{"groupId":"OG002","value":"51.7","spread":null},{"groupId":"OG003","value":"30.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.1","spread":null},{"groupId":"OG001","value":"90.8","spread":null},{"groupId":"OG002","value":"64.2","spread":null},{"groupId":"OG003","value":"87.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.6","spread":null},{"groupId":"OG001","value":"92.9","spread":null},{"groupId":"OG002","value":"66.5","spread":null},{"groupId":"OG003","value":"94.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.1","spread":null},{"groupId":"OG001","value":"95.0","spread":null},{"groupId":"OG002","value":"61.6","spread":null},{"groupId":"OG003","value":"98.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.6","spread":null},{"groupId":"OG001","value":"99.4","spread":null},{"groupId":"OG002","value":"80.0","spread":null},{"groupId":"OG003","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"98.8","spread":null},{"groupId":"OG002","value":"74.5","spread":null},{"groupId":"OG003","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"97.6","spread":null},{"groupId":"OG002","value":"65.0","spread":null},{"groupId":"OG003","value":"98.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.1","spread":null},{"groupId":"OG001","value":"96.9","spread":null},{"groupId":"OG002","value":"57.5","spread":null},{"groupId":"OG003","value":"97.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Count of Participants by Anti-HBs Titer Categories","description":"Count of participants by antibody titer against hepatitis B surface antigen (anti-HBs), categorized using cutoffs at 5, 10, 100 and 1000 mIU/mL. The testing assay lower limit of quantitation was 5 mIU/mL and upper limit 1000 mIU/mL. Study visit weeks are according to protocol-specified visit windows; anti-HBs results outside visit windows were not included. Because high proportions of participants achieved anti-HBs above the assay upper limit of quantitation, the planned geometric mean analysis was not conducted. Instead, anti-HBs were summarized according to the categories shown in the Data Table below.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"52","spread":null},{"groupId":"OG002","value":"80","spread":null},{"groupId":"OG003","value":"46","spread":null}]},{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"5","spread":null}]},{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"46","spread":null},{"groupId":"OG002","value":"36","spread":null},{"groupId":"OG003","value":"10","spread":null}]},{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"49","spread":null},{"groupId":"OG002","value":"36","spread":null},{"groupId":"OG003","value":"8","spread":null}]},{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"18","spread":null},{"groupId":"OG003","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"52","spread":null},{"groupId":"OG003","value":"7","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"10","spread":null},{"groupId":"OG003","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"37","spread":null},{"groupId":"OG002","value":"36","spread":null},{"groupId":"OG003","value":"24","spread":null}]},{"measurements":[{"groupId":"OG000","value":"72","spread":null},{"groupId":"OG001","value":"68","spread":null},{"groupId":"OG002","value":"46","spread":null},{"groupId":"OG003","value":"28","spread":null}]},{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"53","spread":null},{"groupId":"OG002","value":"29","spread":null},{"groupId":"OG003","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"47","spread":null},{"groupId":"OG003","value":"4","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"9","spread":null},{"groupId":"OG003","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"38","spread":null},{"groupId":"OG002","value":"42","spread":null},{"groupId":"OG003","value":"19","spread":null}]},{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"71","spread":null},{"groupId":"OG002","value":"50","spread":null},{"groupId":"OG003","value":"38","spread":null}]},{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"48","spread":null},{"groupId":"OG002","value":"19","spread":null},{"groupId":"OG003","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"50","spread":null},{"groupId":"OG003","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"13","spread":null},{"groupId":"OG003","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"50","spread":null},{"groupId":"OG003","value":"14","spread":null}]},{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"79","spread":null},{"groupId":"OG002","value":"42","spread":null},{"groupId":"OG003","value":"34","spread":null}]},{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"49","spread":null},{"groupId":"OG002","value":"9","spread":null},{"groupId":"OG003","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"25","spread":null},{"groupId":"OG003","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"28","spread":null},{"groupId":"OG003","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"28","spread":null},{"groupId":"OG002","value":"43","spread":null},{"groupId":"OG003","value":"9","spread":null}]},{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"127","spread":null},{"groupId":"OG002","value":"57","spread":null},{"groupId":"OG003","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"31","spread":null},{"groupId":"OG003","value":"0","spread":null}]},{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"10","spread":null},{"groupId":"OG003","value":"0","spread":null}]},{"measurements":[{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"27","spread":null},{"groupId":"OG003","value":"2","spread":null}]},{"measurements":[{"groupId":"OG001","value":"39","spread":null},{"groupId":"OG002","value":"47","spread":null},{"groupId":"OG003","value":"11","spread":null}]},{"measurements":[{"groupId":"OG001","value":"112","spread":null},{"groupId":"OG002","value":"46","spread":null},{"groupId":"OG003","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"45","spread":null},{"groupId":"OG003","value":"0","spread":null}]},{"measurements":[{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"11","spread":null},{"groupId":"OG003","value":"1","spread":null}]},{"measurements":[{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"32","spread":null},{"groupId":"OG003","value":"5","spread":null}]},{"measurements":[{"groupId":"OG001","value":"70","spread":null},{"groupId":"OG002","value":"48","spread":null},{"groupId":"OG003","value":"25","spread":null}]},{"measurements":[{"groupId":"OG001","value":"79","spread":null},{"groupId":"OG002","value":"24","spread":null},{"groupId":"OG003","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]},{"measurements":[{"groupId":"OG000","value":"5","spread":null}]},{"measurements":[{"groupId":"OG000","value":"39","spread":null}]},{"measurements":[{"groupId":"OG000","value":"84","spread":null}]},{"measurements":[{"groupId":"OG000","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"53","spread":null},{"groupId":"OG003","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"12","spread":null},{"groupId":"OG003","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"32","spread":null},{"groupId":"OG003","value":"10","spread":null}]},{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"76","spread":null},{"groupId":"OG002","value":"39","spread":null},{"groupId":"OG003","value":"32","spread":null}]},{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"55","spread":null},{"groupId":"OG002","value":"17","spread":null},{"groupId":"OG003","value":"27","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Grade ≥2 AEs Post-vaccination Adverse Events","description":"The protocol required reporting of (1) Grade ≥2 AEs, (2) AEs that led to a change in study treatment regardless of grade, (3) AEs meeting serious AE (SAE) definition or expedited AE (EAE) reporting requirement, (4) Grade ≥1 local and systemic injection reactions within 7 days of any study vaccine injection, (5) medically attended adverse events (MAAE) regardless of grade, and (6) potential immune-mediated AEs regardless of grade. This outcome is limited to the Grade ≥2 AEs that occurred within 4 weeks after any study vaccination. Grading was per DAIDS AE Grading Table (Version 2.1): Grade 1 (mild), 2 (moderate), 3 (severe), 4 (life-threatening) and 5 (death). DAIDS EAE Manual (V1.0) was used. Wilson method was used for confidence intervals.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.7","spread":null},{"groupId":"OG001","value":"45.7","spread":null},{"groupId":"OG002","value":"43.5","spread":null},{"groupId":"OG003","value":"48.6","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Primary Seroprotection Response by Sex","description":"Subgroup analysis of the primary seroprotection response outcome measure (as described in the Primary Outcome Measure 1 above) by sex. Descriptive summary of the SPR by subgroups; the study was not powered for testing the success of HEPLISAV-B vaccination within subgroups.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.4","spread":null},{"groupId":"OG001","value":"98.5","spread":null},{"groupId":"OG002","value":"89.7","spread":null},{"groupId":"OG003","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"75.7","spread":null},{"groupId":"OG003","value":"100","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Primary Seroprotection Response by Race","description":"Subgroup analysis of the primary seroprotection response outcome measure (as described in the Primary Outcome Measure 1 above) by race. Descriptive summary of the SPR by subgroups; the study was not powered for testing the success of HEPLISAV-B vaccination within subgroups.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.4","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"80.0","spread":null},{"groupId":"OG003","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.5","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"92.3","spread":null},{"groupId":"OG003","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.7","spread":null},{"groupId":"OG001","value":"98.0","spread":null},{"groupId":"OG002","value":"67.7","spread":null},{"groupId":"OG003","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.6","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"100","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":187},"commonTop":["Injection site pain","Headache","Fatigue","Malaise","Myalgia"]}}}